We are live on ! Find out more
SLG

Stanley-Laman Group Portfolio holdings

AUM $814M
1-Year Est. Return 40.24%
This Fund
S&P 500
This Quarter Est. Return
+5.38%
1 Year Est. Return
+40.24%
3 Year Est. Return
+82.87%
5 Year Est. Return
+77.64%
10 Year Est. Return
+275.61%
AUM
$407M
AUM Growth
-$38.3M
Cap. Flow
-$52.4M
Cap. Flow %
-12.88%
Top 10 Hldgs %
19.3%
Holding
282
New
19
Increased
67
Reduced
110
Closed
63

Top Buys

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$6.14M
2
ADAP
Adaptimmune Therapeutics
ADAP
+$5.93M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.36M
4
ALBO
Albireo Pharma Inc
ALBO
+$1.07M
5
ZYME icon
Zymeworks
ZYME
+$808K

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$8.83M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.78M
3
LJPC
La Jolla Pharmaceutical Company
LJPC
+$4.57M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.53M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$966K

Sector Composition

Rank Sector Weight
1 Industrials 19.96%
2 Technology 18%
3 Healthcare 15.75%
4 Materials 7.84%
5 Financials 7.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLL
101
DELISTED
L3 Technologies, Inc.
LLL
$1.12M 0.27%
5,250
-108
-2% -$22.5K
SPY icon
102
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$1.11M 0.27%
3,837
-924
-19% -$263K
MRK icon
103
Merck
MRK
$315B
$1.1M 0.27%
16,271
-8,011
-33% -$510K
GD icon
104
General Dynamics
GD
$99.7B
$1.1M 0.27%
5,367
-126
-2% -$24.7K
LDOS icon
105
Leidos
LDOS
$13.4B
$1.09M 0.27%
15,799
+404
+3% +$27.4K
JNJ icon
106
Johnson & Johnson
JNJ
$609B
$1.09M 0.27%
7,882
-230
-3% -$30.6K
ALBO
107
DELISTED
Albireo Pharma Inc
ALBO
$1.08M 0.27%
+32,788
New +$1.07M
IJH icon
108
iShares Core S&P Mid-Cap ETF
IJH
$122B
$1.07M 0.26%
26,715
-50
-0.2% -$2.01K
DCI icon
109
Donaldson
DCI
$10.5B
$1.06M 0.26%
18,157
+493
+3% +$24.8K
CYAD
110
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$1.05M 0.26%
39,750
+1,225
+3% +$35.9K
CTS icon
111
CTS Corp
CTS
$1.7B
$1.05M 0.26%
30,537
+1,588
+5% +$57.3K
ORCL icon
112
Oracle
ORCL
$364B
$1.03M 0.25%
19,976
+280
+1% +$13.6K
SBUX icon
113
Starbucks
SBUX
$120B
$1.02M 0.25%
18,023
+159
+0.9% +$8.41K
ESNT icon
114
Essent Group
ESNT
$6.15B
$1.02M 0.25%
23,059
+1,055
+5% +$43.3K
NDAQ icon
115
Nasdaq
NDAQ
$51.8B
$1.02M 0.25%
35,547
+186
+0.5% +$5.73K
CE icon
116
Celanese
CE
$5.01B
$1M 0.25%
8,811
+28
+0.3% +$3.21K
HXL icon
117
Hexcel
HXL
$7.83B
$990K 0.24%
14,768
+593
+4% +$40.2K
EVRG icon
118
Evergy
EVRG
$19.7B
$972K 0.24%
17,700
+89
+0.5% +$5.03K
RGA icon
119
Reinsurance Group of America
RGA
$15.8B
$970K 0.24%
6,713
+90
+1% +$12.7K
PF
120
DELISTED
Pinnacle Foods, Inc.
PF
$954K 0.23%
14,712
+241
+2% +$15.9K
HURC icon
121
Hurco Companies Inc
HURC
$142M
$946K 0.23%
20,982
+516
+3% +$22.7K
AMGN icon
122
Amgen
AMGN
$198B
$945K 0.23%
4,559
+32
+0.7% +$6.31K
CELG
123
DELISTED
Celgene Corp
CELG
$923K 0.23%
10,318
-53
-0.5% -$4.68K
MXIM
124
DELISTED
Maxim Integrated Products
MXIM
$912K 0.22%
16,169
+350
+2% +$21.1K
BRSS
125
DELISTED
Global Brass & Copper Hldgs, Inc
BRSS
$903K 0.22%
24,481
+805
+3% +$28.2K
3 4
5
6 7

Similar funds

VFG
Victory Financial Group Austin, Texas $814M AUM 18.17% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $816M AUM 34.73% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $812M AUM 17.34% 1-Year Est. Return
UAG
United Advisor Group Cincinnati, Ohio $811M AUM 18.32% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
BC
Brio Consultants San Francisco, California $818M AUM 13.48% 1-Year Est. Return

Stanley-Laman Group's Q3 2018 Portfolio in Review

As of Q3 2018, Stanley-Laman Group held 282 positions worth $407M, down 8.6% from $445M the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Stanley-Laman Group withdrew a net $52.4M in Q3 2018, closing 63 positions and reducing 110 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $8.83M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 20% of assets, up from 18% a quarter earlier, followed by Technology and Healthcare.

Against the trend, Stanley-Laman Group opened a new position in Acceleron Pharma worth $7.16M.

  • Stanley-Laman Group's largest Q3 2018 buy was Acceleron Pharma: 125,020 shares worth $7.16M.
  • Stanley-Laman Group added most to Prudential Financial in Q3 2018, an estimated $152K increase.
  • Stanley-Laman Group's biggest Q3 2018 reduction was Hortonworks, Inc., cutting an estimated $629K.
  • Stanley-Laman Group fully exited Neurocrine Biosciences in Q3 2018, selling an estimated $8.83M.
  • Stanley-Laman Group's ten largest holdings make up 19% of its $407M portfolio in Q3 2018.
  • Stanley-Laman Group opened 19 new positions and closed 63 in Q3 2018.
  • Stanley-Laman Group's portfolio value fell 8.6% quarter-over-quarter to $407M.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.